Search research articles
Contact Us
Filters
Showing results (691-700 of 754) with videos related to
Page
of 76
Sort By:
American Heart Journal
|
May 13, 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Rhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
European Journal of Heart Failure
|
December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial data
Offer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
The New England Journal of Medicine
|
November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Circulation. Heart Failure
|
August 30, 2024
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial
Henri Lu, Safia Chatur, Sahmin Lee, et al.
Journal of Cardiac Failure
|
April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Eugene Braunwald, et al.
European Heart Journal
|
November 4, 2004
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry
Eric J Velazquez, Gary S Francis, Paul W Armstrong, et al.
Circulation. Heart Failure
|
December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial
Sanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
Journal of the American College of Cardiology
|
April 23, 2021
Incidence and Outcomes of Pneumonia in Patients With Heart Failure
Li Shen, Pardeep S Jhund, Inder S Anand, et al.
Page
of 76
Search research articles
Search
Showing results (691-700 of 754) with videos related to
Sort By:
Page
of 76
American Heart Journal
|
May 13, 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Rhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
European Journal of Heart Failure
|
December 18, 2024
Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial data
Offer Amir, Gabby Elbaz-Greener, Shemy Carasso, et al.
The New England Journal of Medicine
|
November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Circulation. Heart Failure
|
August 30, 2024
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial
Henri Lu, Safia Chatur, Sahmin Lee, et al.
Journal of Cardiac Failure
|
April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Eugene Braunwald, et al.
European Heart Journal
|
November 4, 2004
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry
Eric J Velazquez, Gary S Francis, Paul W Armstrong, et al.
Circulation. Heart Failure
|
December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial
Sanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
Journal of the American College of Cardiology
|
April 23, 2021
Incidence and Outcomes of Pneumonia in Patients With Heart Failure
Li Shen, Pardeep S Jhund, Inder S Anand, et al.
Page
of 76